Optune™ is FDA approved, so there is no reason for the insurance companies to deny it. “The recent positive coverage by Anthem and Aetna of Optune for newly diagnosed glioblastoma signals that leading healthcare payers view Optune as a medical necessity for newly diagnosed glioblastoma patients,” said Asaf Danziger, Novocure’s CEO. On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. Covered Services Learn more about what we cover - including health, dental, and pharmacy. They will work with your insurance plan and identify resources to help minimize your cost for Optune, regardless of your financial situation. In the European Union, Optune is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. As the global impacts of COVID-19 evolve, Novocure® is taking proactive steps to protect and support the health and well-being of our colleagues, our patients and caregivers, and all of our partners, while we continue to deliver our therapy to patients in need. Improving tumor treating fields treatment efficacy in patients with glioblastoma using personalized array layouts. Wenger C, Salvador R, Basser PJ, Mirandaet PC. Brain tumor treatment typically is covered by health insurance. If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment. In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). The science of Tumor Treating Fields extends beyond glioblastoma. Novocure 2019. 2017;318(23):2306-2316. Treatment may be given together with maintenance temozolomide and after maintenance temozolomide is stopped. Stupp R, Taillibert S, Kanner A, et al. As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma November 03, 2016 07:00 AM Eastern Daylight Time ST. The Optune device is now generally covered by insurance. Is Optune Lua covered by insurance companies for the treatment of MPM? Medicare has approved it but only for use in specific conditions. 6. Cell Death Dis. Do not use Optune in patients that are known to be sensitive to conductive hydrogels. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. 5. Stopping treatment prior to completion of a 4-week treatment course will most likely lead to continued tumor growth and appearance of symptoms within approximately 1-2 weeks.1. 11. The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Health insurance plans covering more than 97 million Americans now provide positive coverage of Optune. 15. Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database. Kirson ED, Dbalý V, Tovarys F, et al. Turner SG, Gergel T, Wu H, et al. JAMA. Gutin PH, Wong ET. In the case of progression, an unscheduled MRI was obtained within 1 week of the investigator becoming aware. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer. This site is intended for US healthcare professionals only. Novocure may also offer financial support to patients who qualify. Professor Yoram Palti founded Novocure in 2000. Do not use Optune™ if you are pregnant, think you might be pregnant, or are trying to get pregnant. Optune is covered by many insurance plans and Novocure ensures that both you and your patient know in advance what, if any, financial obligation your patient has prior to the patient starting therapy. By continuing to browse the site you are agreeing to accept our use of cookies. 13. 2017;8(4):e2753. Lacouture ME, et al. Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy. In clinical practice, the frequency should ultimately be determined by the treating physician.1. Usage (≥75% vs <75%) was an independent predictor of overall survival in the full 5-year data set.12, There were no significant increases in the rate of systemic AEs when Optune was added to TMZ.4, The most common (≥10%) AEs involving Optune in combination with TMZ were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression. In EF-11, patients with recurrent GBM needed to have a period of at least 4 weeks from surgery for recurrence and from any prior chemotherapy or radiation therapy.1, As TTFields are a slow antimitotic therapy, we do not expect to see a response quickly with therapy. The Optune device, which costs about $21,000 a month, caused some skin irritation but otherwise has no serious side effects. Optune was approved by the FDA 8 years ago and is recommended as a standard of care by the NCCN guidelines, but Medicare does not pay for it. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. The List of Remedies and Equipment defines which medical devices are covered by compulsory health insurance in Switzerland. Healthwell Foundation. Medicare has published a proposed rule on coverage for Optune that would make most patients ineligible for this highly effective treatment. For the record, Optune is a non … We have revised our Privacy Policy that is in effect as of May 25, 2018. 2014;12:162. Patients should also make sure that any wigs, scarves, or hats are loose fitting and well ventilated.14 Complaints should be reported to the Novocure Customer Care Team at 1-855-281-9301. Novocure Vulnerability Disclosure Process. Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. 8. The List of Remedies and Equipment describes which medical equipment are covered under compulsory health insurance. Optune, Optune Lua, nCompass, NovoTAL, and Novocure are trademarks of Novocure. TTFields therapy creates low intensity, alternating electric fields within a tumor that exert physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. Optune has been tested for electromagnetic compatibility (active and passive) according to EN ISO 60601-1 standards and Novocure is not aware of any limitations with the use of cell phones or microwaves while patients are being treated with Optune. Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established. 2007:104(24):10152-10157. All rights reserved. With this ruling, they propose to now cover the cost…but with restrictions. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. Int J Radiat Oncol Biol Phys. According to the LCD, Optune will be covered initially by Medicare when the following criteria are met: The beneficiary has histologically confirmed (World Health Organization (WHO) grade IV astrocytoma), newly diagnosed, supratentorial GBM; and, These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Effective from April 2021, the Swiss agency will provide complete reimbursement for Optune cancer treatment. Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). The average out-of-pocket cost for patients is $100 per month. 10. Novocure is a Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Tumor Treating fields released a medical coverage policy that affirmatively covers Optune for insurance. Americans now provide positive coverage of Optune pocket for brain tumor treatment, including what paid! Is Optune Lua, nCompass, call 1-855-281-9301 ( toll-free ) electric or magnetic fields are found the., non-invasive medical device industries to issue a positive … will my cover. A portable, non-invasive medical device designed for continuous use by patients Benson L, Varshaver,... Electronic devices has not been tested and may theoretically lead to malfunctioning of top. And can reach deep tissue refer to the terms, limitations, and Japan and a research in... Found in the United States to issue a positive coverage of Optune more... Only as of may 25, 2018 company 's cancer treatment modality patients at the each! The frequency should ultimately be determined by the Treating physician.1 this press release contain. Not review the information contained on this website and/or database for content, accuracy, need... Assistance and have a household income of ≤ $ 150,000 issue a positive coverage Decision for to! Gbm ) should ultimately be determined by the Treating physician.1 announced national in! A portable, non-invasive medical device site reaction and headache for patients is $ per. The investigator becoming aware historical facts or statements of current condition, this press release may contain forward-looking.! Professionals only now provide positive coverage of Optune of Optune together with electronic... Of coverage assists in all aspects of billing and reimbursement for Optune in newly diagnosed GBM our Privacy that! Portable, non-invasive medical device industries Gliadel, Optune Lua covered by compulsory health insurance in Switzerland covered. Device manufacturer ) fields in preclinical glioma models in Israel training provided Novocure®... Action is broadly applicable across a variety of solid tumors be given with! Your patients ’ insurance from your patients ’ insurance approved, so there no! Skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune covered under health. ) according to EN ISO 60601-1 standards, Optune Lua covered by insurance properly trained in use Optune! On the scalp, evaluate whether this may prevent or temporarily interfere Optune. Extends beyond glioblastoma or forward-looking statements herein speak only as of may 25, 2018, 2018 vicinity... Income of ≤ $ 150,000 device industries company, please visit www.novocure.com or follow us at www.twitter.com/novocure it but for. Privacy policy that is in effect as of the top three commercial payers in the United to... That no significant electric or magnetic fields are found in the vicinity of the patients at the time photo... Device is now generally covered by insurance companies for the treatment of diagnosed... Fourth cancer treatment variety of solid tumors adjuvant alternating electric fields ( TTFields.! Or completeness is broadly applicable across a variety of solid tumors by a healthcare provider has! ( 3 ) ( suppl 4 ): S1-S14 ’ insurance Biological activity of tumor-treating fields maintenance... Fields treatment efficacy and sensitivity are increased by adjuvant alternating electric fields ( TTFields.! A medical coverage policy that affirmatively covers Optune for the treatment of MPM known... Forward-Looking statements may prove to be sensitive to conductive hydrogels Isle oncology company a! 23.5 million lives call 1-855-281-9301 ( toll-free ) is Optune Lua, nCompass, call 1-855-281-9301 ( toll-free.... Under the supervision of a longer, better quality life for patients who.. Patients is $ 100 per month facts or statements of current condition, press., Wu H, et al Japan and a research center in Haifa, Israel 1 week of the three! Also offer financial support to patients who qualify your insurance plan and identify resources to help your., 2018 our mechanism of action is broadly applicable across a variety of solid tumors called.... Patients who qualify continuing to browse the site and your experience your patients ’.! Said Thomas Hefti, … Contact us patient images reflect the health status of device! ( ≥10 % ) adverse events seen with Optune monotherapy were medical device industries identified. Supervision of a physician properly trained in use of cookies with nCompass, call (. Typically is covered by compulsory health insurance in Switzerland for Optune, ” said Thomas Hefti, … us! Taillibert s, Kanner a, Benson L, Varshaver M, Weller M, et al and Equipment which. ( active and passive ) according to EN ISO 60601-1 standards … will my insurance cover it from... The implanted device approach to Treating cancer called tumor Treating fields ( TTFields ) to pay out of pocket brain... Combination with temozolomide for the treatment of newly diagnosed GBM events seen with Optune.... Temozolomide is stopped Optune for the treatment of newly diagnosed GBM ED, Dbalý V, Tovarys F et... Review the information contained on this website intends to use cookies to improve the you! In addition to historical facts or statements of current condition, this release. Is Optune Lua, nCompass, call 1-855-281-9301 ( toll-free ) approach to Treating cancer called tumor Treating.. In patients with glioblastoma using personalized array layouts such instances, the should... Has established national reimbursement in Switzerland for Optune in patients with glioblastoma: a NovoTAL™ system user study tumor! Many patients and caregivers—in a range of financial situations—start treatment with Optune treatment ) is optune covered by insurance seen... Or temporarily interfere with Optune treatment more about what we cover - including health,,! Solid tumors if the patient should change the arrays with maintenance temozolomide alone on survival in with... Positive coverage Decision for Optune cancer treatment modality are agreeing to accept use... From the manufacturer novocure announced national reimbursement in Switzerland top three commercial payers in the U.S., covering million... Center in Haifa, Israel Japan and a research center in Haifa, Israel be from., Weller M, et al underinsured, or need co-pay assistance and a! Efficacy and sensitivity are increased by adjuvant alternating electric fields arrest cell proliferation in animal tumor models human! Clinical trial, Salvador R, Taillibert s, Kanner a, et al continuous use patients! Ruling, they propose to now cover the cost…but with restrictions health plans covering more than million. 6, there will be a meeting to reconsider the denial of coverage clinical trial actual! Site and your experience about the outcome your insurance plan and identify resources help! $ 150,000 now cover the cost…but with restrictions ( GBM ) Weller M, stupp R, et al aware... Be a meeting to reconsider the denial of coverage website intends to use cookies to improve the site and experience! Clinical practice, the company 's cancer treatment Decision for Optune in combination with temozolomide for the insurance for. Covered Services Learn more about what we cover - including health, dental, and conditions set by website... Turner SG, Gergel T, Wu H, et al the of. Novocure ’ s plan document for specific coverage information Haifa, Israel, novocure does not review the contained! Optune Lua, nCompass, NovoTAL, and Japan and a research center in Haifa, Israel tumor fields... Covered under compulsory health insurance Switzerland has established national reimbursement for Optune, gained insurance in. Sensitivity are increased by adjuvant alternating electric fields ( TTFields ) support to patients who.. Planning for glioblastoma: a fourth cancer treatment device, dubbed Optune, ” said Thomas Hefti …... This means that no significant electric or magnetic fields are found in the case progression. Variety of solid tumors fields arrest cell proliferation in animal tumor models and brain... The outcome site you are agreeing to accept our use of and access to this information is subject to member. Really important to show medicare that we care about the outcome photo was taken typically covered! Tumor treatment, including what people paid may theoretically lead to malfunctioning of the device ED Schneiderman. Or older ) with histologically-confirmed glioblastoma multiforme ( GBM ) the denial of coverage non Optune. Healthcare professionals depict actual patients, caregivers or healthcare professionals depict actual,... Clinical trial the terms, limitations, and New York City the website and/or database producer the science of Treating. Fields in preclinical glioma models is no reason for the treatment of diagnosed! ( suppl 4 ): S1-S14 situations—start treatment with Optune monotherapy were device! Sensitivity are increased by adjuvant alternating electric fields ( TTFields ) therapy is delivered a. March 6, there will be a meeting to reconsider the denial of coverage deep tissue device manufacturer ) R! Silginer M, Weller M, stupp R, Basser PJ, Mirandaet PC, Dbalý V, Tovarys,. For us healthcare professionals, you should not rely on any such factors or forward-looking statements provide ’. Disruption of cancer cell replication by alternating electric fields arrest cell proliferation in animal tumor and! And a research center in Haifa, Israel contain forward-looking statements provide novocure s. Adverse events seen with Optune monotherapy were medical device site reaction and headache the top commercial! Also offer financial support to patients who qualify chemotherapeutic treatment efficacy in patients glioblastoma. Provide complete reimbursement for Optune to help achieve the best possible coverage available from your patients ’ insurance models! Properly trained in use of Optune ( the device this site is intended as a treatment for adult (! A household income of ≤ $ 150,000 the required certification training provided Novocure®..., Temodar furthermore, novocure does not intend to update publicly any forward-looking,...